NCT06849609View on ClinicalTrials.gov

A Study to Evaluate the Tolerability, Safety and Efficacy of VGN-R13 in Patients with ALS

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

January 16, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

June 30, 2026

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

BIOLOGICAL

VGN-R13

An adeno-associated viral vector 9 gene therapy product.

Trial Locations (1)

Unknown

RECRUITING

TongJi Hospital, Wuhan

All Listed Sponsors

lead

Hong Chen

OTHER